Aquestive Therapeutics (NASDAQ:AQST) Issues Earnings Results, Misses Expectations By $0.13 EPS

Aquestive Therapeutics (NASDAQ:AQST) released its quarterly earnings data on Wednesday. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.13), FiscalAI reports. The business had revenue of $13.02 million for the quarter, compared to the consensus estimate of $13.28 million.

Aquestive Therapeutics Price Performance

Shares of AQST stock opened at $4.37 on Thursday. The stock’s 50-day moving average is $4.28 and its 200 day moving average is $5.20. Aquestive Therapeutics has a 1-year low of $2.12 and a 1-year high of $7.55. The company has a market cap of $533.14 million, a P/E ratio of -6.15 and a beta of 1.61.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on AQST. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Wednesday, January 21st. Lake Street Capital set a $6.00 target price on Aquestive Therapeutics in a report on Tuesday, February 3rd. Piper Sandler raised their price target on Aquestive Therapeutics from $5.00 to $8.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Finally, Wall Street Zen lowered shares of Aquestive Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, January 31st. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Aquestive Therapeutics presently has an average rating of “Buy” and a consensus price target of $8.50.

More Aquestive Therapeutics News

Here are the key news stories impacting Aquestive Therapeutics this week:

• Positive Sentiment: Company issued FY2026 revenue guidance of $46.0–$50.0 million, a range that overlaps and reaches slightly above the consensus estimate (~$47.4M), which investors may interpret as supportive of near‑term top‑line visibility. Aquestive Reports Q4 and FY2025 Results and Business Update
• Neutral Sentiment: Analysts hold mixed views on Aquestive alongside other healthcare names, reflecting divergent expectations that could widen trading volatility as investors digest guidance and results. Analysts Have Conflicting Sentiments on These Healthcare Companies
• Neutral Sentiment: Previews and metric breakdowns ahead of/after the print provide context on revenue drivers and year‑over‑year comparisons; useful for investors assessing whether misses reflect one‑time items or slowing demand. Compared to Estimates, Aquestive Therapeutics (AQST) Q4 Earnings: A Look at Key Metrics
• Negative Sentiment: Q4 results missed expectations: EPS of ($0.26) vs. consensus ($0.13) and revenue $13.02M vs. $13.28M expected — the miss is the primary near‑term negative catalyst behind volatility. Aquestive Therapeutics (AQST) Reports Q4 Loss, Misses Revenue Estimates
• Negative Sentiment: A securities‑litigation reminder from Faruqi & Faruqi, LLP highlights potential legal overhang for shareholders and can add downside risk or increased volatility if pursued. AQST SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims
• Neutral Sentiment: Reported short‑interest figures in recent headlines contain anomalous/zero values and appear unreliable; treat short‑interest signals cautiously until corrected data is available.

Institutional Trading of Aquestive Therapeutics

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its position in shares of Aquestive Therapeutics by 30.8% in the 3rd quarter. Vanguard Group Inc. now owns 5,662,132 shares of the company’s stock worth $31,651,000 after buying an additional 1,333,627 shares during the last quarter. Federated Hermes Inc. lifted its position in Aquestive Therapeutics by 159.4% during the fourth quarter. Federated Hermes Inc. now owns 2,032,822 shares of the company’s stock valued at $13,132,000 after acquiring an additional 1,249,044 shares during the last quarter. Wells Fargo & Company MN boosted its stake in Aquestive Therapeutics by 804.6% in the fourth quarter. Wells Fargo & Company MN now owns 1,188,531 shares of the company’s stock valued at $7,678,000 after acquiring an additional 1,057,145 shares in the last quarter. State Street Corp grew its holdings in Aquestive Therapeutics by 53.7% in the fourth quarter. State Street Corp now owns 2,462,778 shares of the company’s stock worth $15,910,000 after purchasing an additional 860,562 shares during the last quarter. Finally, Wasatch Advisors LP acquired a new position in shares of Aquestive Therapeutics during the third quarter worth $4,049,000. 32.45% of the stock is currently owned by institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.